Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction

M. Joerger; A.D. Huitema; D. Koeberle; H. Rosing; J.H. Beijnen; F. Hitz; T. Cerny; J.H.M. Schellens; S. Gillessen

doi:10.1007/s00280-013-2327-2

Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction

M. Joerger
, A.D. Huitema
, D. Koeberle
, H. Rosing
, J.H. Beijnen
, F. Hitz
, T. Cerny
, J.H.M. Schellens
, S. Gillessen

extern

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

PURPOSE: We assessed the impact of hepatic dysfunction on the safety and pharmacology of gemcitabine/capecitabine in patients with advanced pancreatico-biliary cancer. METHODS: We included 12 patients receiving 3 weekly gemcitabine 1,000 mg/m(2) day 1, 8 and oral capecitabine 650 mg/m(2) b.i.d. over 2 weeks until disease progression or intolerable toxicity. Patients were included into one normal hepatic function cohort [total bilirubin (TB) 80 mumol/L). Three patients with a creatinine clearance

Original language	English
Pages (from-to)	113-124
Number of pages	12
Journal	Cancer Chemotherapy and Pharmacology
Volume	73
Issue number	1
DOIs	https://doi.org/10.1007/s00280-013-2327-2
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00280-013-2327-2

Cite this

@article{eacdcf806de941cc82afc172e9d04e8a,

title = "Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction",

abstract = "PURPOSE: We assessed the impact of hepatic dysfunction on the safety and pharmacology of gemcitabine/capecitabine in patients with advanced pancreatico-biliary cancer. METHODS: We included 12 patients receiving 3 weekly gemcitabine 1,000 mg/m(2) day 1, 8 and oral capecitabine 650 mg/m(2) b.i.d. over 2 weeks until disease progression or intolerable toxicity. Patients were included into one normal hepatic function cohort [total bilirubin (TB) 80 mumol/L). Three patients with a creatinine clearance",

author = "M. Joerger and A.D. Huitema and D. Koeberle and H. Rosing and J.H. Beijnen and F. Hitz and T. Cerny and J.H.M. Schellens and S. Gillessen",

year = "2014",

doi = "10.1007/s00280-013-2327-2",

language = "English",

volume = "73",

pages = "113--124",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction

AU - Joerger, M.

AU - Huitema, A.D.

AU - Koeberle, D.

AU - Rosing, H.

AU - Beijnen, J.H.

AU - Hitz, F.

AU - Cerny, T.

AU - Schellens, J.H.M.

AU - Gillessen, S.

PY - 2014

Y1 - 2014

N2 - PURPOSE: We assessed the impact of hepatic dysfunction on the safety and pharmacology of gemcitabine/capecitabine in patients with advanced pancreatico-biliary cancer. METHODS: We included 12 patients receiving 3 weekly gemcitabine 1,000 mg/m(2) day 1, 8 and oral capecitabine 650 mg/m(2) b.i.d. over 2 weeks until disease progression or intolerable toxicity. Patients were included into one normal hepatic function cohort [total bilirubin (TB) 80 mumol/L). Three patients with a creatinine clearance

AB - PURPOSE: We assessed the impact of hepatic dysfunction on the safety and pharmacology of gemcitabine/capecitabine in patients with advanced pancreatico-biliary cancer. METHODS: We included 12 patients receiving 3 weekly gemcitabine 1,000 mg/m(2) day 1, 8 and oral capecitabine 650 mg/m(2) b.i.d. over 2 weeks until disease progression or intolerable toxicity. Patients were included into one normal hepatic function cohort [total bilirubin (TB) 80 mumol/L). Three patients with a creatinine clearance

U2 - 10.1007/s00280-013-2327-2

DO - 10.1007/s00280-013-2327-2

M3 - Article

SN - 0344-5704

VL - 73

SP - 113

EP - 124

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 1

ER -

Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this